tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schmidt LE et al. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. 2003 Transplantation pmid:12883193
Sheiner PA et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. 1994 Transplantation pmid:7513099
Troppmann C et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. 2003 Transplantation pmid:12883205
Therapondos G et al. Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? 2003 Transplantation pmid:12883220
Marcos A et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. 2004 Transplantation pmid:15480160
Burroughs TE et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 2007 Transplantation pmid:17452891
Ellis D et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. 1999 Transplantation pmid:10532541
Migita K et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. 1999 Transplantation pmid:10532544
Méndez A et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. 2014 Transplantation pmid:24492423
Moss MC et al. Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? 2014 Transplantation pmid:24492429
Todo S et al. Abdominal multivisceral transplantation. 1995 Transplantation pmid:7530873
Wozniak LJ et al. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. 2015 Transplantation pmid:26038872
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Boldt A et al. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. 2006 Transplantation pmid:16906043
Kuypers DR et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. 2010 Transplantation pmid:20555228
Narayanan M et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. 2013 Transplantation pmid:23423268
Reutzel-Selke A et al. Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. 2003 Transplantation pmid:12811235
Gaber AO et al. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. 2013 Transplantation pmid:23423269
Molano RD et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. 2003 Transplantation pmid:12811239
Guethoff S et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. 2013 Transplantation pmid:23423270
Bilolo KK et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. 2003 Transplantation pmid:12811249
Miyakoshi S et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. 2007 Transplantation pmid:17700155
Trancassini M et al. Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. 2001 Transplantation pmid:11707748
Waldman WJ et al. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. 2001 Transplantation pmid:11707749
Huang E et al. Alemtuzumab induction in deceased donor kidney transplantation. 2007 Transplantation pmid:17984833
Jain A et al. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. 2014 Transplantation pmid:25285953
Reese JC et al. The effect of FK506 on canine bile flow. 1993 Transplantation pmid:7504342
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Woodle ES et al. FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. 1993 Transplantation pmid:7504346
Jindal RM et al. Effect of deoxyspergualin on the endocrine function of the rat pancreas. 1993 Transplantation pmid:7504347
Eberhard OK et al. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. 1996 Transplantation pmid:8629294
Millis JM et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. 1996 Transplantation pmid:8629298
Savoldo B et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. 2001 Transplantation pmid:11579304
Jain A et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. 2001 Transplantation pmid:11579306
Egeland EJ et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. 2017 Transplantation pmid:28452920
Sheiner PA et al. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. 1997 Transplantation pmid:9355846
Iyengar AR et al. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. 1997 Transplantation pmid:9158008
van Hooff JP Pneumocystis carinii pneumonia after renal transplantation. 1997 Transplantation pmid:9158038
Reding R et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. 1994 Transplantation pmid:7507272
Hsiau M et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. 2011 Transplantation pmid:21857278
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Yates CJ et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. 2013 Transplantation pmid:23902993
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Hariharan S et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. 1996 Transplantation pmid:8610411
Kitayama T et al. Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. 2003 Transplantation pmid:12605126
Storb R et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. 1993 Transplantation pmid:7692635
Cacciarelli TV et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. 1996 Transplantation pmid:8610416
Egidi MF and Gaber AO Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2003 Transplantation pmid:12605133
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Osowski CL et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. 1996 Transplantation pmid:8610430
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. 2011 Transplantation pmid:21107305
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Yu S et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. 2006 Transplantation pmid:16421475
Jurcevic S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. 1998 Transplantation pmid:9603168
Borrows R et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. 2006 Transplantation pmid:16421488
Macphee IA et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. 2002 Transplantation pmid:12490779
Shapiro AM et al. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. 2002 Transplantation pmid:12490784
First MR et al. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. 2013 Transplantation pmid:23619735
Luan FL et al. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. 2011 Transplantation pmid:21242885
Ho ET et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. 2013 Transplantation pmid:23542469
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Veroux M et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. 2012 Transplantation pmid:22298033
Naesens M et al. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. 2008 Transplantation pmid:18431234
Shapiro R et al. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 1996 Transplantation pmid:8932264
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
Fisher NC et al. The clinical impact of nephrotoxicity in liver transplantation. 2000 Transplantation pmid:10910259
MacDonald AS Management strategies for nephrotoxicity. 2000 Transplantation pmid:10910262
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Reyes J et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. 2000 Transplantation pmid:10910279
Ko S et al. The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. 1995 Transplantation pmid:7539553
Fealy MJ et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. 1995 Transplantation pmid:7539555
Moffatt SD and Metcalfe SM Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. 2000 Transplantation pmid:10836388
Higgins RM et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10836393
Meiser BM The best dosing for initial tacrolimus application is trough level adapted! 2005 Transplantation pmid:15714162
Podesser BK et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. 2005 Transplantation pmid:15714171
Garton T Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. 2002 Transplantation pmid:12352898
Cantarovich D et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. 2005 Transplantation pmid:15714172
Yamauchi A et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. 2002 Transplantation pmid:12352921
Nguyen L et al. Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. 2012 Transplantation pmid:22960763
Thomas PG et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. 2007 Transplantation pmid:17565326
Paterson DL et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. 1998 Transplantation pmid:9753337
Woodle ES et al. Liver transplantation in the first three months of life. 1998 Transplantation pmid:9753340
Radkowski M et al. Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. 1998 Transplantation pmid:9753352
Miao G et al. Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. 2004 Transplantation pmid:15257039
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Peng Y et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. 2013 Transplantation pmid:23263506
Warty V et al. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. 1988 Transplantation pmid:2458643
Kuypers DR et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. 2013 Transplantation pmid:23263559
White M et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. 2006 Transplantation pmid:17006323
Wissing KM et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. 2006 Transplantation pmid:17006324
Günther M et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. 2001 Transplantation pmid:11233913
Rezeig MA et al. Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. 1997 Transplantation pmid:9175820
Hricik DE et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2003 Transplantation pmid:14508357
Foster RD et al. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. 2003 Transplantation pmid:14508367
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526
Uemoto S et al. Experience with FK506 in living-related liver transplantation. 1993 Transplantation pmid:7679528
Talento A et al. A single administration of LFA-1 antibody confers prolonged allograft survival. 1993 Transplantation pmid:7679531
Mor E et al. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7513098